Next generation biologics company Noveome Biotherapeutics will evaluate its lead programme ST266 as a potential treatment of severe cytokine storm response associated with Covid-19.
ST266, which was initially developed by Noveome for ophthalmology indications, is a first-of-its-kind cell-free platform biologic drug, composed of hundreds of anti-inflammatory proteins, known as the secretome.
The proteins are collected from donated, full term caesarean-sectioned placentas, which are normally discarded after birth. In clinical trials to date, ST266 has shown to be safe and effective at reducing inflammatory response in humans.
Read more on pharmaceutical-technology.com